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Platinum agents (cisplatin, carboplatin, and oxaliplatin) are a class of chemotherapy agents that have a broad spectrum of activity
against several solid tumors. Toxicity to the peripheral nervous system is the major dose-limiting toxicity of at least some of the
platinum drugs of clinical interest. Among the platinum compounds in clinical use, cisplatin is the most neurotoxic, inducing
mainly sensory neuropathy of the upper and lower extremities. Carboplatin is generally considered to be less neurotoxic than
cisplatin, but it is associated with a higher risk of neurological dysfunction if administered at high dose or in combination with
agents considered to be neurotoxic. Oxaliplatin induces two types of peripheral neuropathy, acute and chronic. The incidence of
oxaliplatin-induced neuropathy is related to various riskfactors such as treatment schedule, cumulative dose, and timeof infusion.
To date, several neuroprotective agents including thiol compounds, vitamin E, various anticonvulsants, calcium-magnesium
infusions, and other nonpharmacological strategies have been tested for their ability to prevent platinum-induced neurotoxicity
with controversial results. Further studies on the prevention and treatment of neurotoxicity of platinum analogues are warranted.
1.Introduction
Platinum drugs are among the most important cytotoxic
drugs available to oncologists. Although they share some
structural similarities, there are also marked diﬀerences in
their therapeutic use, pharmacokinetics, and adverse eﬀect
proﬁles [1–3]. Cisplatin is the ﬁrst agent of platinum drugs,
which was approved in 1978 for the treatment of testicular
and ovarian cancer [4]. In view of its considerable toxicity
proﬁle, many attempts have been made to develop analogues
with less toxicity, increased eﬃcacy, or both. Carboplatin is
a second-generation platinum drug with equivalent activity,
in some cancer types, to cisplatin. Carboplatin is often
administered in combination with a taxane as a ﬁrst-line
treatment for ovarian cancer [5, 6]. Lung cancer is also
treated with carboplatin in combination with vinorelbine,
gemcitabine,orpaclitaxel[7].Oxaliplatin,athird-generation
platinum drug, is the standard of treatment, together with
5-ﬂuorouracil/leucovorin (5FU/LV), for locally advanced
and metastatic cancer of the colon and rectum [8]. This
paper aims to highlight the neurotoxicity of commonly used
platinum agents and published data on certain compounds
t h a th a v eb e e nr e p o r t e dt oh a v ep r o t e c t i v ee ﬀects when
administered simultaneously with these agents.
2. Cisplatin
Peripheral neurotoxicity is the most important dose-limiting
problem associated with cisplatin [9]. A number of patho-
physiologicalmechanismshavebeenproposedtoexplainthis
phenomenon, with some data suggesting that cisplatin kills
malignant cells and peripheral neurons by means of a sim-
ilar mechanism of apoptosis [10]. Peripheral neurotoxicity
developsinapproximately50%ofpatientsreceivingcisplatin
[11], but the onset of toxicity is delayed until a cumulative
dose higher than 300mg/m2 has been given [12, 13]. Signs
and symptoms of peripheral neurotoxicity involve the upper
andlowerextremitiesandincludelossofvibrationsense,loss
of position sense, tingling paraesthesia, weakness, tremor,
and loss of taste [14–16]. Seizures and leukoencephalopathy
have also been described [17, 18]. After discontinuation
of treatment, the neurological dysfunction may gradually
improve, but it may persist for a period of time, or it can
be permanent [11, 19].2 Chemotherapy Research and Practice
Cisplatin is ototoxic. Tinnitus and hearing loss have been
observed in up to 31% of patients treated with initial intra-
venouscisplatindoseof50mg/m2 [20,21].Transienthearing
loss and mild audiometric abnormalities were observed in
30% of patients receiving 150mg/m2 of cisplatin [22, 23].
The mechanisms of cisplatin-induced damage to the outer
hairy cells of the cochlea probably include the formation
of reactive oxygen radicals and depletion of glutathione
[24]. Other risk factors include simultaneous use of other
potentially ototoxic agents (e.g., aminoglycosides), previous
cranial irradiation, preexisting renal dysfunction, or inner
ear damage [21, 23, 25, 26].
3.Carboplatin
Carboplatin is considered to be less neurotoxic than cis-
platin [27]. Neurological dysfunction is a side eﬀect in the
carboplatin-based regimen but appears later on and mostly
after the administration of carboplatin at high-dose levels
or in combination with other cytotoxic agents known to be
neurotoxic (e.g., taxanes) [5, 6, 28]. Only 4–6% of patients
who receive carboplatin may develop peripheral neuropathy
[29]. Pretreated patients with other neurotoxic agents (e.g.,
cisplatin, and etoposide) and those who are older than 65
years have a higher risk [29, 30].
Ototoxicity, after therapy with carboplatin, is thought to
be rare. A small proportion of patients, about 1.1%, show
symptoms such as tinnitus or subclinical audiographical
changes [31].
4. Oxaliplatin
Oxaliplatin is more like cisplatin in its potential to produce
signiﬁcant neurological dysfunction (Table 1). Peripheral
neuropathy is the most common dose-limiting toxicity
of oxaliplatin, and it is one of the major causes of
discontinuation of therapy. Sensory peripheral neuropathy
caused by administration of oxaliplatin is distinguished in
2 forms: (1) an acute peripheral sensory neuropathy that
may appear during the administration of the drug or after
the ﬁrst few drug infusions and (2) a chronic dose-limiting
cumulative peripheral sensory neuropathy. The mechanisms
underlyingthesetwoformsofoxaliplatin-inducedperipheral
neuropathy have not been clearly deﬁned. Acute neurotoxic
eﬀects may result from the impairment of voltage-gated
sodium channels and occur approximately in 85–95% of all
patients exposed to oxaliplatin [32, 33]. Symptoms consist
mainlyofparesthesiasanddysesthesiasintheextremitiesand
t h ep e r i o r a lr e g i o na n da r ee x a c e r b a t e db yc o l de x p o s u r e .
One other very rare manifestation of acute oxaliplatin-
induced neurotoxicity is laryngopharyngeal dysesthesia, a
transient sensation of diﬃculty in breathing without evi-
dence of respiratory distress [20, 34]. This transient syn-
drome aﬀects approximately 1–2% of patients and recovers
between cycles [35]. The risk of acute neuropathy appears to
be lower if oxaliplatin is administrated in a dose of 85mg/m2
every 2 weeks rather than 130mg/m2 every 3 weeks [33, 34].
The most accepted mechanism of the chronic form
oxaliplatin-induced neurotoxicity is decreased cellular
metabolism and axonplasmatic transport resulting from
the accumulation of oxaliplatin in the dorsal root ganglia
cells. As a result, oxaliplatin produces symmetrical, axonal,
and sensory distal neuropathy [36]. Neurological symptoms
in this form of sensory neurotoxicity are dominated by
pronounced paresthesias and dysesthesias of the extremities
and dysfunction of ﬁne sensory-motor coordination which
may result in impairment of daily life [20, 37]. Other rare
atypical neurosensory symptoms associated with higher
cumulative dose of oxaliplatin (higher than 1000mg) are
those of spinal cord compression (Lhermitte sign) and
urinary retention [38]. The incidence of chronic oxaliplatin-
induced peripheral neuropathy is related to various risk
factors such as cumulative dose, treatment schedule, and
time of perfusion [39]. The peripheral sensory neuropathy
induced by oxaliplatin tends to improve after treatment is
stopped. Symptoms are partly reversible in approximately
80% of patients and resolve completely in about 40% of
patients 6–8 months after the discontinuation of oxaliplatin
treatment [36, 40].
Ototoxicity due to administration of oxaliplatin is very
uncommon [41, 42].
5. Prevention and Treatment of
Platinum-InducedNeurotoxicity
Many studies have examined the eﬃcacy of a number of
potential neuroprotective agents administered together with
platinum analogues. The use of these agents generally aims
to reduce the incidence and severity of the neurotoxicity
without impairing the antitumor eﬃcacy of the platinum
drugs.
5.1. Thiol Compounds. Three thiol compounds have been
studied as neuroprotective agents in patients receiving
cisplatin: amifostine, glutathione, and the melanocortin Org
2766.
Among these agents, glutathione seems to have some
neuroprotective eﬀects in platinum-induced neurotoxicity.
Glutathione has been studied as a chemoprotective agent
in patients receiving chemotherapy with cisplatin in small
randomized trials. Published data are conﬂicting as some
of the studies have shown that glutathione may provide
neuroprotection in patients treated with cisplatin without
altering its antineoplastic eﬀect [37, 43, 44], while others
found no reduction in toxicity [45, 46]. Cascinu et al.
were the ﬁrst to study the potentially protective eﬀect of
glutathione on oxaliplatin neurotoxicity in a randomized,
placebo-controlled clinical trial [47]. This study showed
that glutathione can exert a beneﬁcial eﬀect on oxaliplatin-
induced neurotoxicity without interferences with oxaliplatin
antitumor activity. Other studies, however, have shown no
beneﬁt from the use of glutathione for preventing the
oxaliplatin-induced peripheral neuropathy [48]. In addition,
the fact that elevated intracellular levels of glutathione
have been correlated with increased resistance to platinum
agents raises some concerns over the use of glutathione
as a neuroprotective agent [48–50]. More trials are neededChemotherapy Research and Practice 3
Table 1
Comparison of cisplatin- and oxaliplatin-induced neurotoxicity Cisplatin Oxaliplatin
Dose limiting toxicity Peripheral neurotoxicity Peripheral neurotoxicity
Symptoms Paresthesia Paresthesia, sensory ataxia, and dysesthesia
Location Extremities Extremities, perioral area
Time-course onset Delayed Acute and delayed
After treatment deterioration Recovery
Accompanying toxicities Ototoxicity Laryngospasms
Precipitating factors None Exposure to cold
to conﬁrm the safety and usefulness of glutathione as a
protective agent against platinum-induced neurotoxicity.
In respect to cisplatin-induced ototoxicity, there is some
evidence that amifostine may be useful as a protective agent
[20, 51].
5.2.VitaminE. TheneuroprotectiveroleofvitaminEagainst
cisplatin neurotoxicity has recently been evaluated by Pace et
al. in a randomized, placebo-controlled trial [52]. This was a
phase III study in which 108 patients, treated with cisplatin,
were randomized to receive vitamin E (alpha-tocopherol
400mg/day) or placebo. Class II evidence that vitamin E
supplementation signiﬁcantly reduces the relative risk of
developing signs or symptoms of neurotoxicity (relative risk
= 0.14) (95% conﬁdence interval = 0.02–1.00, P<0.05) was
provided [52].
5.3. Calcium (Ca) and Magnesium (Mg) Infusions. Ca/Mg
infusions have been used to decrease the incidence of
oxaliplatin-induced neuropathy without any inﬂuence on
antitumor activity [53–55]. However, the CONCEPT study
reported that treatment with Ca/Mg decrease antitumor
eﬀect in patients with metastatic colorectal cancer treated
with oxaliplatin, and thus, they are not advisable in combi-
nation with the FOLFOX regimen [56].
5.4. Anticonvulsants (Gabapentin and Pregabalin). Gaba-
pentin is an antiepileptic drug which has been used in the
managementofneuropathicpain.Somestudiesattemptedto
assess the impact of gabapentin on oxaliplatin-induced neu-
rotoxicity, but they could not support a role for gabapentin
in reducing the severity of oxaliplatin-induced neurotoxicity
[57–59].
Pregalin is also an anticonvulsant drug used for neu-
ropathic pain. A case of successful treatment of hyper-
excitability syndrome with pregalin after oxaliplatin and
gemcitabinetherapyforpancreaticcancerhasbeendescribed
[60] .I nar e c e n ts t u d y ,S a i fe ta l .t r e a t e d2 3p a t i e n t s
with gastrointestinal tumors and grade 2 and 3 oxaliplatin-
induced neurotoxicity with pregabalin at a dose of 150mg
orally 3 times a day and found that pregabalin reduced the
severity of oxaliplatin-induced neuropathy [61].
5.5. Other Strategies. Nonpharmacological approaches to
prevent oxaliplatin-induced neurotoxicity include the “stop
and go” concept. This strategy is based on the observation
ofreversibilityofneurotoxicsymptomsafterdiscontinuation
of oxaliplatin. In this approach, patients receive treatment
with oxaliplatin plus 5FU/LV until either the beginning of
the development of peripheral neurotoxicity or a predeter-
mined “time to best response”. Next, maintain ace therapy
with 5FU/LV is continued without oxaliplatin so that any
neurologic damage is given time to recede. Subsequently,
oxaliplatin is reintroduced to maximize the potential eﬀect
of the combination regime [62].
Another strategy suggested by Petrioli et al. involves
longer duration of oxaliplatin administration which is sup-
posed to result in decreased neurotoxicity [63].
6. Conclusions
Platinum compounds are active in the treatment of solid
tumors, but peripheral neuropathy is the major non-
hematological dose-limiting adverse eﬀect especially for
cisplatin and oxaliplatin. Despite the eﬀorts to ﬁnd speciﬁc
agents who will prevent or minimize neurotoxicity caused
by platinum drugs, there is no eﬀective strategy for the
management of the neurotoxicity induced by platinum
agents. Unfortunately, none of the symptomatic treatments
discussed above have proven useful. Therefore, new drugs or
strategies for the prevention and amelioration of platinum-
induced neurotoxicity must be found.
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